Brian Nowosielski

In part 3 of our interview with Bill Wolfe, COO of WriteWise, he discusses the technology backing his team’s approach to forever changing how pharmacy benefits are distributed in the US.

Amid recent measles outbreaks in Texas and Ohio, researchers aim to understand MMR vaccine coverage following postelimination outbreaks throughout the country.

Lissette Logan, PharmD, COO at OvaryIt, joined Drug Topics to discuss the fragmentation of contraceptive care in the US and how pharmacists are uniquely positioned to provide these services.

Based on a new report detailing the current trends in PBM types from the Big 3 to new grassroots organizations, Bill Wolfe, COO of WriteWise, discusses a shifting pharmacy benefits landscape.

Researchers address impacts of the Inflation Reduction Act on the access, cost, and coverage of glucagon-like peptide-1 medications for patients with diabetes.

In the final part of our interview with Mark Garofoli, PharmD, BCGP, CPE, CTTS, he discusses what the future will hold regarding clinical decision-making following the reported acetaminophen-autism link.

Pain medication expert Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, joined Drug Topics to explore the referenced studies in the Trump Administration’s push to link acetaminophen use with autism.

Bill Wolfe, COO at WriteWise and former President of Aetna’s Pharmacy Management team, discusses the evolution of pharmacy benefits and where PBM and pharmacist roles fall in between.

Amid the prominent use of vaping in today’s society, researchers assess how it impacts pregnancy outcomes, including preterm birth, low birth weight, and small for gestational age.

As GLP-1 popularity, use, and price continues to rise, pharmacy industry stakeholders are attempting to guide pharmacists and patients around the complexities of this drug class.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, also known as “the Pain Guy,” discusses his initial reactions upon learning about the Trump Administration linking acetaminophen use with autism.

In part 3 of our interview with Rae McMahan, she explores her role at Prescryptive Health and how she’s helping pharmacy stakeholders navigate complex GLP-1 prescription drug benefits.

The model is designed to increase access, utilization, and adherence to insulin by lowering its maximum price.

Pooja Babbrah, executive vice president of strategy and industry alignment at NCPDP, joined Drug Topics to discuss the power of pharmacy standards in helping patients, pharmacists, and more.

Along with the Senior Care Pharmacy Coalition, 3 additional long-term care advocacy groups have joined in on calls to pass the Preserving Patient Access to Long-Term Care Pharmacies Act.

Through her work as senior vice president of payor solutions at Prescryptive Health, Rae McMahan shares insights into how increased GLP-1 popularity and costs impact pharmacies.

As their scope of practice continues to expand, researchers issue a survey on how community pharmacists conduct point-of-care testing for acute upper respiratory tract infections.

Rae McMahan, senior vice president of payor solutions at Prescryptive Health, discusses GLP-1 access, advertising, and the challenges that often accompany this drug class.

The clinical impact of sodium-glucose cotransporter 2 inhibitors on adults with type 2 diabetes calls for further research on the risk factors of treatment failure and patients’ economic outcomes.

Athena Rae Roesler, MPH, and Anna Lin-Schweitzer, MPH, from the Milken Institute, discuss pharmacists’ role as essential care partners that improve a variety of health concerns for their community’s patients.

Saeed Aboelzahab, director of consumer health at Cardinal Health, discusses the opportunities for community pharmacies to grow revenue through Medicare Advantage OTC benefits.

Chris Bell, JD, vice president of business operations at API Warehouse, discusses proactive approaches in preventing fraudulent threats and staying compliant with DSCSA.

This year’s event, from October 18-21, 2025, will take place in New Orleans, Louisiana, at the Ernest N. Morial Convention Center.

While experts agree there is no one-size-fits-all approach, addressing medication nonadherence among patients presents opportunities for pharmacists to set themselves apart as medication counselors.

In an exploration of cardiovascular outcomes, health care utilization, and patient costs, researchers compare glucagon-like peptide-1s with alternative noninsulin glucose-lowering therapies.

This episode explores how recent trends in the retail community pharmacy industry are informing the actions of pharmacy leadership and their teams across the country.

In part 3 of our interview with Andrew Maiorini, PharmD, FAHM, vice president of clinical programs at PerformRx, he discusses the ways in which his company is helping patients stay adherent on their medications.

Calvin Hunsicker, founder & chief product officer at SureCost, discusses ongoing pharmacy procurement challenges in 2025 and how his company is helping businesses tackle common obstacles.

Among adults with type 1 diabetes, researchers explore how additional autoimmune diseases impacted patients’ physical and mental health burdens.

In a world of decreasing access to medications that are rising dramatically in price, Andrew Maiorini, PharmD, FAHM, reminds us of the power of patient engagement and communication.